206 results about "Drugs sensitivity" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of sesquiterpenoids and / or pharmaceutically acceptable salts thereof in preparation of medicines for treating or preventing infectious diseases caused by staphylococcus aureus. The invention relates to the field of medicines, in particular to application in preparation of medicines for treating or preventing infectious diseases caused by drug-sensitive staphylococcus aureus or drug-resistant staphylococcus aureus. The structure of the sesquiterpenoids is shown as a formula I in the specification. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low. The sesquiterpenoids shown in the formula I have a very good activity inhibition effect on staphylococcus aureus for the first time, and the sesquiterpenoids have a very good activity inhibition effect on staphylococcus aureus with drug sensitivity, drug medium or drug resistance.

According to the device and the reagent for extracting the pathogen, the pathogen product separated from the uncultured sample extracted by using the device and the reagent can be subjected to a drug sensitivity test after simple culture and bacteria collection treatment, so that the culture process is shortened compared with pathogen diagnosis and identification of a clinical infected sample, and a drug sensitivity result can be obtained more quickly; and a more timely diagnosis and treatment reference is provided for clinicians.

The invention discloses a dual-channel fusion cancer drug response prediction method, and belongs to the technical field of biological information. The method aims at solving the problems that an existing prediction method is only limited to intra-modal feature extraction, and a complex nonlinear cooperative relation between a drug and cancer cells is difficult to capture. Multi-omics data, drug molecular structure information and cancer cell line drug reaction data are integrated from databases such as CCLE, GDSC and PubChem, and unified input features are formed through standardization and feature construction. Introducing a hierarchical double-attention conversion network into the first channel to carry out characterization learning on the multi-modal features of the drug and the cell line, and constructing a high-order attention neighbor interaction graph convolutional network in the second channel to capture graph structure information of cancer drug response. And carrying out adaptive weighting on output results of the two channels by using a PPO-based fusion module so as to realize a dynamic optimal decision. And finally, generating a drug sensitivity prediction result of the cancer cell line through a classification predictor.

The invention relates to a model based on multi-modal cross attention and uncertainty integral gradient and application, and relates to the technical field of bioinformatics. The model is obtained based on multi-modal cross attention and uncertainty integral gradient construction, the problems that in an existing drug sensitivity prediction method, multi-modal data fusion is difficult, the model generalization ability is weak, and interpretability is lacked can be solved, the model captures correlation between modals through a cross attention mechanism, and the prediction accuracy of the drug sensitivity is improved. According to the method, uncertainty estimation is realized by combining Monte Carlo Dropout (MC Dropout), feature importance is analyzed by using an integral gradient algorithm, and finally, unification of high-precision prediction and biological interpretability is realized.

According to the trace pathogen enrichment device and the detection method provided by the invention, pathogen products separated from uncultured samples extracted by using the device can be subjected to drug sensitivity test after simple culture and bacteria collection treatment, so that the culture process is shortened compared with pathogen diagnosis and identification of clinical infected samples, a drug sensitivity result can be obtained more quickly, and the detection efficiency is improved. And a more timely diagnosis and treatment reference is provided for clinicians.

The application discloses a microbial drug sensitivity detection method. The application comprises: loading a microbial database, establishing a corresponding relationship between secondary microbial names and primary categories; loading a drug breakpoint database based on the "antimicrobial drug sensitivity experiment execution standard"; placing a standard culture dish in an image acquisition device to acquire an image, and calibrating an image analysis system with a vernier caliper; inputting sample information to be detected, acquiring and uploading the image; an image analysis system extracts the position of a drug sensitivity paper sheet, identifies the edge of a bacterial inhibition zone and calculates the diameter; the system extracts corresponding drug breakpoint thresholds based on the microbial category, compares the measured diameter and determines the sensitivity classification (S / I / R); and finally, the result is uploaded to a LIS system. The method can realize the automation, standardization and high efficiency of drug sensitivity detection.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

The invention belongs to the technical field of strain identification and drug sensitivity detection, and discloses a strain identification and drug sensitivity detection kit and a preparation method and application thereof, the kit comprises a drug sensitivity disc, a pre-enrichment chromogenic culture medium, a chromogenic culture medium, sterile water and a diluent; the drug sensitive disc body comprises an enterobacteriaceae area, an enterococcus area, a staphylococcus area, a pseudomonas aeruginosa area and an acinetobacter baumannii area; the enterobacteriaceae area is provided with enterobacteriaceae identification culture medium micropores and drug micropores, the enterococcus area is provided with enterococcus identification culture medium micropores and drug micropores, the staphylococcus area is provided with staphylococcus identification culture medium micropores and drug micropores, and the pseudomonas aeruginosa area is provided with pseudomonas aeruginosa identification culture medium micropores and drug micropores. An acinetobacter baumannii identification culture medium micropore and a medicine micropore are matched in the acinetobacter baumannii area; the problems that an existing drug sensitivity test mode is complex in operation, high in cost and low in accuracy of identification and detection results are solved.

The present application relates to the technical field of knowledge graph, in particular to a multi-task hepatitis B drug screening method and system based on knowledge graph assistance, comprising the following steps: based on hepatitis B virus genotype sequence data recorded over time, patient drug use records and drug sensitivity. In the present application, multi-dimensional dynamic time series data such as virus genotype sequence data, patient drug use records and drug sensitivity are integrated, the interaction events between entities are marked by time stamp, the dynamic characteristics such as virus variation track and drug efficacy change are embedded in the graph node attributes, so that the knowledge representation can reflect the time dependence in the real scene. Based on biological pathway annotation information and protein interaction data, the hyperedge connection multi-entity set is defined, the limitation of traditional knowledge graph which only supports binary relationship is expanded, the drug combination and multi-target synergistic mechanism are explicitly modeled, and the misjudgment of combination effect caused by the simplification of interaction relationship is avoided.

The invention belongs to the cross technical field of veterinary medicine and biomedicine, and relates to a construction and evaluation method of a dog spontaneous breast cancer organoid model, which specifically comprises the following steps: (1) obtaining dog spontaneous breast cancer tissues through operation or biopsy, separating tumor tissues under sterile conditions, and carrying out fine enzymolysis digestion treatment to obtain dog spontaneous breast cancer tissues; obtaining a single-cell suspension; and (2) inoculating the single-cell suspension into a three-dimensional culture system, carrying out three-dimensional culture by adopting a culture medium containing EGF, FGF and B27 in combination with a growth factor, promoting the growth and amplification of the breast cancer organs, and carrying out timely passage according to the growth condition so as to maintain the activity of the model. The model constructed by the invention completely retains genetic heterogeneity and pathological microenvironment of primary tumors, does not need gene editing, is simple and convenient to operate and low in cost, is particularly suitable for individual drug sensitivity detection of pet dogs, and provides an efficient and high-simulation experimental platform for dog breast cancer mechanism research and clinical precise medication.

The application relates to a clinical microbiological examination drug sensitivity test report automatic generation device, and belongs to the technical field of medical instruments. A fixing assembly is arranged in a box body to fix a culture dish at the center of the bottom of a cavity, so that a cavity top measuring assembly can be used to collect a drug sensitivity type label on the culture dish and measure the diameter of a bacteriostatic circle in the culture dish, the artificial measurement efficiency is improved, and the occurrence of false reports is avoided, the accuracy of drug sensitivity results is improved, and a disinfection and sterilization assembly is arranged in the box body, so that sample cross contamination and laboratory pollution are effectively avoided.

The invention provides a method for treating AR negative TNBC through combination of quercetin and enzalutamide, the quercetin up-regulates the AR expression level by inhibiting a high-expression solute carrier SLC7A5, so that tumor cells which are not sensitive to enzalutamide originally obtain drug sensitivity again; the combined use of an AR antagonist enzalutamide (1-80 [mu] M) can cooperatively block an AR signal channel and significantly inhibit cell proliferation (the inhibition rate of drug combination is 70%, Plt, 0.01 higher than that of a single drug). In-vitro experiments prove that the scheme has a synergistic effect (the effect is optimal when the mass ratio is 1: 1-5: 1) in MDA-MB-231 cells, and an animal model shows that the tumor volume inhibition rate reaches 70% or above. Safety evaluation shows that the drug combination does not cause abnormity of serum biochemical indexes (ALT / AST / BUN / CREA) or damage of main organs and tissues. The invention further provides a preparation method of an oral preparation (tablets / capsules / nanoparticles) containing quercetin (50-500 mg / day) and enzalutamide (40-160 mg / day), and a new strategy is provided for reversing AR-TNBC drug resistance.

The invention provides a cancer subtype classification method, system, equipment and program product based on ferroptosis related miRNA, and belongs to the field of intelligent medical treatment. The breast cancer is divided into four subtypes on the basis of ferroptosis related miRNA, the breast cancer FAP + subtype is identified on the basis of ferroptosis activity, the molecular characteristics of the FAP + subtype of an individual breast cancer patient are measured by establishing FAPscore, and the higher the FAPscore is, the more remarkable the FAP + subtype characteristics of the breast cancer patient are. The invention also finds that FAPscore can be used for predicting response, prognosis and drug sensitivity of individual cancer patients to immunotherapy response, and the discovery has wide cross-cancer species applicability and is not limited to breast cancer. The invention provides a new insight for a more effective and individualized treatment strategy of cancer.

The application discloses a quantum weak measurement real-time detection method and system for studying the drug efficiency of acrolein. The application uses the quantum weak measurement method to realize real-time, label-free and quantitative monitoring of the interaction process between acrolein and organoids, obtains drug efficiency evaluation parameters such as a steady-state response amplitude, an initial response rate, a steady-state time and / or an estimated absorption / binding amount, and can realize in-vitro drug sensitivity stratification and tolerance-related phenotype evaluation in combination with an organoid activity readout. When the sample shows reduced absorption / binding amount and / or reduced kinetic rate, it can be indicated that there is an 'absorption deficiency type tolerance-related phenotype', which is used for further mechanism research and drug strategy optimization. The technology has the advantages of good real-time performance, few sample processing steps, clear application scene and the like.

The invention discloses an application of an ARRB1 inhibitor in preparation of a tumor drug resistance reversal agent or a tumor drug sensitizer. It is found that by reducing ARRB1 expression, the sensitivity of human breast cancer cells to etoposide can be improved, the drug resistance of breast cancer etoposide can be reversed, and an ARRB1 inhibitor can be combined with an anti-tumor drug etoposide for use to improve the treatment effect. The invention provides a new direction for research and development of drugs for overcoming breast cancer treatment drug resistance, and has important clinical application value and development value.

The utility model relates to a mycoplasma culture drug sensitivity detection card, and belongs to the technical field of drug sensitivity detection, the mycoplasma culture drug sensitivity detection card comprises a bottom plate, a sample bottle is inserted in the front surface of the bottom plate, the front surface of the bottom plate is provided with a sealing assembly, and the back surface of the bottom plate is provided with a protection assembly. According to the mycoplasma culture drug sensitivity detection card, through the arrangement of the bottom plate and the cover plate, stable storage of a solution is facilitated, the use stability of the detection card is improved, control over different variables of the solution is facilitated, and the use convenience is improved; the whole detection card can be protected, the use stability can be improved, the marking opening is covered by the movable assembly, the detection information can be protected, the use stability of the whole detection card can be further improved, and the whole detection card is simple in structure, convenient and stable to use and good in use effect.

The invention relates to a culture medium for constructing and / or culturing a sarcoma-like organ, a method for constructing and / or culturing the sarcoma-like organ by using the culture medium, a sarcoma tissue dissociation digestive juice and a kit for constructing and / or culturing the sarcoma-like organ. The culture medium disclosed by the invention not only can construct and obtain high-quality sarcoma organs at a relatively high success rate, but also can support long-term stable culture of the sarcoma organs. The sarcoma tissue dissociation digestive juice not only can efficiently dissociate sarcoma tissues, but also can retain living tumor cells to the maximum extent, so that the construction success rate of sarcoma organs is further improved. Therefore, according to the sarcoma organ culture medium and the culture system thereof, high-quality sarcoma organs can be stably obtained, key technical support is provided for pathological mechanism research, drug sensitivity detection, personalized treatment scheme formulation and the like of sarcoma diseases, and the culture medium and the culture system have clear and important clinical transformation value and industrialization potential.

The invention discloses a construction method of a synovial sarcoma tumor ball vascular induction model, the model and application of the synovial sarcoma tumor ball vascular induction model. The construction method of the synovial sarcoma tumor sphere vascular induction model comprises the following steps: S1, suspension culture of synovial sarcoma organs; and S2, constructing a synovial sarcoma tumor ball vascular induction model based on the culture chip. When the synovial sarcoma organ is cultured, the synovial sarcoma primary tissue is cultured in a suspension culture mode, and the method not only can improve the proliferation speed of the synovial sarcoma organ, the cell growth state is better, the activity is higher, but also has the advantage of simplicity in operation. Besides, the synovial sarcoma tumor sphere vascular induction model is constructed based on the culture chip, and the model can simulate tumor microenvironment more truly, has tumor-related fibroblast and vascular components, and provides more clinical drug sensitivity test results.

The invention belongs to the technical field of biomedical material engineering, and discloses a hydrogel scaffold used for 3D tumor sphere culture and drug screening, the scaffold is formed by four-arm polyethylene glycol maleimide, fibrinogen and thrombin through Michael addition crosslinking and biopolymerization synergistically, the elastic modulus of 10-1000 Pa can be adjusted by regulating and controlling the proportion of all the components, and the hydrogel scaffold can be used for 3D tumor sphere culture and drug screening. Gel forming is completed within 5 min at the room temperature. The scaffold has the biological activity of fibrous protein and the structural stability of polyethylene glycol, can efficiently support HCT116 cells to form high-activity tumor balls, accurately simulate the in-vivo tumor microenvironment and remarkably improve the accuracy and repeatability of drug screening, is easy and convenient to operate, is compatible with a standard pore plate high-throughput platform and is suitable for drug sensitivity detection of personalized treatment of tumors.

The application discloses application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and the antifungal drugs, and relates to the technical field of antifungal drugs. It is found through systematic in-vitro drug sensitivity test that natural product gynostemma pentaphyllum saponin H combined with specific azole antifungal drugs (especially posaconazole POS) can produce significant synergistic antifungal effect, especially for clinical thorny aspergillus, candida, new cryptococcus and dark fungi. The combination strategy can significantly reduce the minimum inhibitory concentration of azole drugs, reverse drug resistance, and is effective for multi-drug resistant strains (such as candida auris). The application provides an efficient and low-toxicity new combination drug scheme for overcoming the increasingly serious fungal drug resistance problem.

The invention provides a kit for predicting drug sensitivity or drug resistance of a lung adenocarcinoma patient and a method for predicting response of the lung adenocarcinoma patient to immune checkpoint inhibitor treatment. The kit comprises a detection reagent for detecting the expression level of the ELAVL1 gene or protein in a sample. The kit provided by the invention can accurately predict the sensitivity or drug resistance of a lung adenocarcinoma patient to various drugs, and realizes prognosis evaluation and sensitivity and drug resistance prediction of the patient; in addition, the immunotherapy benefit people can be precisely layered, the treatment waste and adverse reaction risk of non-benefit patients are reduced, and the treatment efficiency is improved.

The application relates to the technical field of biological medicine, and discloses siRNA for inhibiting a P311 gene, a composition and application thereof. The siRNA can specifically knock down P311 gene expression in human tumor cells, can be used as an auxiliary component for improving the drug efficacy of gemcitabine, can improve the drug sensitivity of a pancreatic cancer patient to gemcitabine, can reduce the gemcitabine drug resistance of a pancreatic cancer patient in an advanced stage, can improve the prognosis of the pancreatic cancer patient, can prolong the survival period of the pancreatic cancer patient in the advanced stage, and has important significance for the treatment of pancreatic cancer.

The application provides a preparation method and application of a bone and soft tissue sarcoma organoid. A bone and soft tissue sarcoma tissue sample is placed in a modified organoid culture medium and placed in a CO2 incubator for culture at 37 DEG C. Half of the medium is replaced every two days, and a bone and soft tissue sarcoma organoid can be obtained within two weeks. The method is simple to operate, significantly improves the survival rate and quantity of organoids, and shortens the culture time of organoids. Eight different subtypes of bone and soft tissue sarcoma organoids can be obtained by using the method. The bone and soft tissue sarcoma organoids obtained by the application can be passaged and stored at low temperature, retain all cell types of the original tumor tissue block, more truly simulate the tumor microenvironment, and provide more clinically consistent drug sensitivity test results. The bone and soft tissue sarcoma organoids obtained by the application can be used for personalized CAR-T treatment evaluation, drug sensitivity detection of chemotherapeutic drugs and targeted drugs, and preparation of personalized tumor vaccines.

This invention discloses a strain of *Bacillus saeformis* H1, its culture method, and its applications, relating to the field of microbial technology. The strain was deposited on March 31, 2026, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 38117. This strain exhibits strong environmental adaptability, can stably grow under neutral to strongly alkaline conditions, and secretes antibacterial substances with low toxicity and no pathogenicity. After optimization, its optimal liquid fermentation conditions are: 5 g / L yeast extract, 10 g / L peptone, 37 g / L sucrose, pH=10, temperature 25℃, rotation speed 140 rpm, and culture time 24 h. The fermentation supernatant of this strain shows significant inhibitory effects on Gram-positive bacteria such as *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus*, and *Streptococcus pneumoniae*, and can be prepared into drug sensitivity tablets. The *Bacillus saeformis* H1 provided by this invention can be used to prepare antibacterial drugs or antibacterial infection drugs, providing a new strategy for alleviating the problem of antibiotic resistance.

The invention provides a color feature extraction and correction method and system for drug sensitive plate MIC value interpretation and a computer readable storage medium. The method comprises the following steps: acquiring a to-be-processed drug sensitive plate image; performing visual preprocessing such as exposure, contrast and white balance on the image according to the configuration file; high-precision alignment correction of the image is realized by using ORB feature detection and a BFMatcher matching algorithm; generating a transparent mask with an Alpha channel based on predefined hole position contour data, and performing non-destructive target segmentation on the aligned image; and converting the target region to an HSV color space, extracting H-channel hue features, executing cyclic correction, eliminating the problem of numerical value jump of the red region, and obtaining stable color feature data. The method has the advantages of being high in image registration precision, accurate in segmentation, stable in color feature, high in robustness and the like, and automatic and standardized interpretation of the MIC value of the drug sensitive plate can be achieved under different shooting conditions.

The application belongs to the technical field of medical information, and discloses a tumor chemotherapy scheme individualized adjustment and curative effect evaluation method and system. Static basic data, dynamic treatment data, single cell sequencing data and structured data of doctor-patient conversation are comprehensively collected in the data fusion quality control stage. Format adaptation and semantic alignment of cross-modal data are realized through a unified standardized interface. Data quality control is carried out in combination with an isolated forest algorithm, and only high-quality data with a score of 80 or more are included to provide a reliable basis for scheme development. In the multi-module collaborative prediction stage, a medical knowledge graph and a hybrid modeling framework are fused, multi-center data is jointly trained, and drug sensitivity scores are accurately output. When the scheme is generated, the clinical guidelines and patient needs are linked, multi-constraint rule reasoning and multi-objective optimization are used to develop individualized schemes that adapt to the patient's genetic characteristics, pathological types and quality of life demands, and reduce the risk of poor efficacy and serious adverse reactions caused by individual differences.

The application provides a single bacterium identification method, system, device, medium and drug sensitivity detection method based on lens-free imaging, and belongs to the technical field of biological image processing. The single bacterium identification method based on lens-free imaging comprises steps of gray scale processing, edge detection and single bacterium identification, and further comprises steps of background removal, abnormal pixel correction, signal enhancement and outlier screening. The single bacterium identification method, system, device and medium have the advantages of high speed and high accuracy. Further used for bacterial drug sensitivity detection, the proliferation of bacteria can be obtained in a short time, and then the minimum inhibitory concentration of antibiotics is obtained, which has great application value.

The invention discloses gastric cancer drug sensitivity testing equipment, and relates to the technical field of drug sensitivity testing, the gastric cancer drug sensitivity testing equipment comprises an operation table, the operation table is rotatably provided with a turntable for supporting a culture dish, the guide frame is mounted at the edge of the top surface of the operation table, a supporting table is slidably mounted in the guide frame, and an eccentric table is telescopically arranged on the side surface of the supporting table; a tool sleeve is further obliquely installed at the bottom of the eccentric table, and a coating rod which is matched with the tool sleeve to evenly smear bacterial liquid in the culture dish is inserted into the bottom of the tool sleeve. The sliding base can drive the supporting table to slide down, so that the coating rod below the tool sleeve makes contact with the inner wall of the culture dish, and then the culture dish is driven to rotate along with the rotating disc; and the distance between the eccentric table and the supporting table is adjustable, so that the coating rod displaces, the end of the coating rod can be adjusted to be attached to the side wall of the culture dish as much as possible, and the whole culture dish can be conveniently and completely coated with the bacterial liquid.

This invention discloses a dosage analysis method for anesthetic drugs during surgery in patients with hypertension, hyperlipidemia, and hyperglycemia. This method integrates multi-source heterogeneous health data from the patient over the past five years to construct a personalized, structured health record. During anesthesia induction, based on the patient's individualized pharmacokinetic model and assessed drug interaction risks, it calculates and recommends precisely adjusted induction doses. During anesthesia maintenance, it innovatively decodes specific EEG signals to establish a dynamic mapping relationship between neurophysiological characteristics and pharmacokinetics. Based on EEG characteristics reflecting drug sensitivity and pain perception, it automatically and in real-time adjusts the predicted concentration of the target drug, achieving closed-loop precise control based on direct feedback from the central nervous system. The system automatically identifies all medications used by the patient, generates a drug interaction risk assessment report using a massive knowledge base, and dynamically updates the risk level and sends warnings during surgery based on real-time vital signs.